학술논문
Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial
Document Type
Article
Author
Heijerman, H.G.M.; McKone, E.F.; Downey, D.G.; Van Braeckel, E.; Rowe, S.M.; Tullis, E.; Mall, M.A.; Welter, J.J.; Ramsey, B.W.; McKee, C.M.; Marigowda, G.; Moskowitz, S.M.; Waltz, D.; Sosnay, P.R.; Simard, C.; Ahluwalia, N.; Xuan, F.; Zhang, Y.; Taylor-Cousar, J.L.; McCoy, K.S.; McCoy, K.; Donaldson, S.; Walker, S.; Chmiel, J.; Rubenstein, R.; Froh, D.K.; Neuringer, I.; Jain, M.; Moffett, K.; Taylor-Cousar, J.L.; Barnett, B.; Mueller, G.; Flume, P.; Livingston, F.; Mehdi, N.; Teneback, C.; Welter, J.; Jain, R.; Kissner, D.; Patel, K.; Calimano, F.J.; Johannes, J.; Daines, C.; Keens, T.; Scher, H.; Chittivelu, S.; Reddivalam, S.; Klingsberg, R.C.; Johnson, L.G.; Verhulst, S.; Macedo, P.; Connett, G.; Nash, E.; Withers, N.; Lee, T.; Bakker, M.; Heijerman, H.; Vermeulen, F.; Knoop, C.; De Wachter, E.; van der Meer, R.; Merkus, P.; Majoor, C.
Source
In: The Lancet . (The Lancet, 23 - 29 November 2019, 394(10212):1940-1948)
Subject
Language
English
ISSN
1474547X
01406736
01406736